Considerable progress in different fields of neuroimmunological research has led to a major increase in the therapeutic options available for the treatment of multiple sclerosis over the last decade. This progress not only includes advances in our understanding of the pathophysiology of MS, and biotechnological developments but also improvements in clinical trial design. Here, we will review pathophysiological aspects, clinical rationale and practical issues of current MS therapy.